🔎 Trials Near Me

Početna › Imunoblastna limfadenopatija › New York

Kliničke studije za Imunoblastna limfadenopatija u državi New York

5 studija za Imunoblastna limfadenopatija traži sudionike na lokacijama u državi New York.

Gradovi u državi New York

Službeni tekst studije (engleski)

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • i još 5
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • Icahn School of Medicine at Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • Weill Cornell Medicine, New York
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06561048

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

  • Clinical Trial Site, New York
  • Clinical Trial Site, New York
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06393738

A Registry for People With T-cell Lymphoma

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
  • Memorial Sloan Kettering Westchester (All protocol activities), Harrison
  • Weill Cornell Medical Center (Data Collection Only), New York
  • i još 2
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 20. svi 2026. · NCT05978141

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

  • Columbia University, New York
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2025. · NCT04234048

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.